ClinicalTrials.gg
Enrolling by invitationNCT07860970Updated Oct 6, 2026

Comparison of Functional Outcomes Between Triceps Tongue Elevation vs Olecranon Osteotomy in Intra Articular Distal Humerus Fracture (IA-DH) Management

An interventional study of Triceps tongue elevation and Olecranon osteotomy in Intra Articular Distal Humerus Fracture, sponsored by Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi · Not applicable, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
15 Years to 75 Years
Sex
All
01

Study summary

Comparison of triceps tongue elevation vs olecranon osteotomy in intra articular distal humerus fracture management by doing Randomized control trial in trauma and orthopedic surgery department of Rawalpindi Teaching Hospital involving participants are 102 in 9 month duration by using MEPI score.

Read the detailed description

Comparison of triceps tongue elevation vs olecranon osteotomy in intra articular distal humerus fracture management by doing Randomized control trial in trauma and orthopedic surgery department of Rawalpindi Teaching Hospital involving participants are 102 with 51 in each in 9 month duration by using MEPI score.

02

Conditions studied

  • Intra Articular Distal Humerus Fracture

Browse trials for

03

In context

Humeral Fractures

106 studies on the registry are indexed under Humeral Fractures; 20 are open to participants now.

This study's planned enrollment of 102 is above the median of 56 across 64 interventional studies indexed under Humeral Fractures.

Browse Humeral Fractures studies →

Lead sponsor

Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both Gender . Age 15-75 Years . (?) Radiologically confirmed intra-articular distal humerus fractures r Patients presenting within 7 days of injury

Exclusion criteria

Exclusion Criteria:

  • Open fractures (Gustilo-Anderson Grade II or higher) . Pathological fractures (e.g., due to tumors or metabolic bone disease) r Previous elbow surgery or deformity on the affected limb Patients with associated neurovascular injury o Patients with comorbidities impairing rehabilitation (e.g., severe stroke, advanced arthritis) . Non-compliance with follow-up protocol
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Olecranon osteotomy

    Olecranon osteotomy will be performed for intra articular distal humerus fracture and outcomes will be assessed

    Procedure: Olecranon osteotomy

  • Experimental
    Triceps tongue elevation

    Triceps tongue elevation will be performed for intra articular distal humerus fracture and outcomes will be assessed

    Procedure: Triceps tongue elevation

Interventions

  • ProcedureTriceps tongue elevation

    Compare the outcomes of triceps tongue elevation and olecranon osteotomy in treatment of intra articular distal humerus fracture.

  • ProcedureOlecranon osteotomy

    Olecranon osteotomy procedure for distal intra articular humerus fracture.

06

What researchers measure

Primary outcomes

  1. MEPI score

    It describes Pain,Stability, Range of motion and personal chores

    Time frame: At 3months and 6 month

  2. MEPI score

    It describes pain,stability, Range of motion and personal chores.

    Time frame: At 3months and 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individuals participant data is not publically available due to institutional privacy policy but can be availed from corresponding author on request

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.

Of 26 interventional studies with no phase under Humeral Fractures, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Sep 19, 2026
Primary completionEst.
May 19, 2027
CompletionEst.
May 19, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860970
Lead sponsor
Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi
Responsible party
Saad Ahmed Khokhar (Postgraduate Resident Trauma and orthopedics, Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi) — Principal investigator
First posted
Oct 6, 2026
Start date
Sep 19, 2026
Primary completion
May 19, 2027 (estimated)
Completion
May 19, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Saad Riaz, FCPS
study chair · Rawalpindi Teaching Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion